Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab

Abstract

Objective: Clinical trials have shown the efficacy of adalimumab in Crohn's disease, but the outcome in regular practice remains unknown. The aim of the study was to examine clinical status, quality of life, and work productivity of Crohn's disease patients receiving adalimumab for one year in the context of usual clinical practice.Material and methods: This was a prospective, observational study with a one-year follow-up. After baseline, Crohn's disease patients were evaluated at 1, 3, 6, 9, and 12 months after starting treatment with adalimumab. Outcome variables included: clinical status (measured with CDAI), quality of life (measured with EuroQoL-5D and IBDQ), and work productivity (measured with WPAI questionnaire). These outcome variables were compared using the Student's t test or Wilcoxon test for paired comparison data according to the data distribution. Statistical significance was set at two-sided p < 0.05. Results:The sample was composed of 126 patients (age Conclusions: In regular practice, adalimumab is clinically effective in the treatment of Crohn's disease patients and results in a significant improvement in quality of life and work productivity.

<p>Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn’s Disease: A Population-Based Cohort Study</p>

“…Tumor necrosis factor (TNF) inhibitors, initially recommended only for patients with inadequate response to conventional therapy, are nowadays used earlier during the disease course, 1 sometimes in a topdown-approach, rather than step-up. 2 Clinical trials have evaluated the effects of TNF inhibitors on work productivity mainly by the Work Productivity and Activity Index [3][4][5][6][7][8][9][10] (Supplementary Table 1). Data from clinical trials have shown a decrease in patient-reported absenteeism during treatment with TNF-inhibitors [3][4][5][6][7]9,10 in selected populations with short follow-up (weeks or months).…”

“…2 Clinical trials have evaluated the effects of TNF inhibitors on work productivity mainly by the Work Productivity and Activity Index [3][4][5][6][7][8][9][10] (Supplementary Table 1). Data from clinical trials have shown a decrease in patient-reported absenteeism during treatment with TNF-inhibitors [3][4][5][6][7]9,10 in selected populations with short follow-up (weeks or months). [3][4][5][6]8,9 However, the longterm effect of TNF-inhibitors in routine clinical practice is not known, and data on work ability during other treatments, including surgery, are sparse.…”

The need for interdisciplinary quality of life studies for patients with Crohn's Disease - a systematic review

“…The analysis of Polish and foreign literature about Qol of CD patients is usually discussed by scientists representing medical fields, mainly in the specialization of gastrology and surgery. These studies, however, focus mainly on medical variables such as: type of treatment [28][29][30][31][32][33][34] surgical interventions [35][36] intestinal resections [37][38][39] or nutrition [40].…”

Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment

“…Clinically meaningful changes in mean SIBDQ total scores at week 24 were seen in naïve patients as well as in the subgroup of infliximab non-responders [ 57 ]. In clinical practice, Saro et al observed, in a prospective study with 126 CD patients, a significant increase in the IBDQ in the first year after starting adalimumab [56.7 (51.6–61.5) to 67.5 (60.1–73.6)] p < 0.05 [ 58 ].…”